Molecular epidemiology: On the path to prevention?

Journal of the National Cancer Institute

Volumn 92, Issue 8, 2000, Pages 602-612

  Perera, Frederica P ^a  

^a Department of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFLATOXIN B1; BENZENE; CARCINOGEN; POLYCYCLIC AROMATIC HYDROCARBON; TOBACCO SMOKE;

BREAST CANCER; CANCER EPIDEMIOLOGY; CANCER PREVENTION; CANCER RISK; CARCINOGENESIS; CASE CONTROL STUDY; CHROMOSOME ABERRATION; CIGARETTE SMOKING; CONTROLLED STUDY; ENVIRONMENTAL EXPOSURE; HEALTH CARE POLICY; HUMAN; LEUKEMIA; LIVER CANCER; LUNG CANCER; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT;

EID: 0034685493     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/92.8.602     Document Type: Review

References (141)

1. Perera FP, Weinstein IB. Molecular epidemiology and carcinogen-DNA adduct detection: new approaches to studies of human cancer causation. J Chronic Dis 1982;35:581-600.
2. Committee on Biological Markers of the National Research Council. Biological markers in environmental health research. Environ Health Perspect 1987;74:3-9.
3. Perera FP. Molecular cancer epidemiology: a new tool in cancer prevention. J Natl Cancer Inst 1987;78:887-98.
4. Hulka BS. ASPO Distinguished Achievement Award Lecture. Epidemiological studies using biological markers: issues for epidemiologists. Cancer Epidemiol Biomarkers Prev 1991;1:13-9.
5. Harris C. Chemical and physical carcinogenesis: advances and perspectives for the 1990s. Cancer Res 1991;51(18 Suppl):5023s-5044s.
6. Schulte, PA, Perera, FP, editors. Molecular epidemiology: principles and practices. New York (NY): Academic Press; 1993.
7. Ambrosone CB, Kadlubar FF. Toward an integrated approach to molecular epidemiology. Am J Epidemiol 1997;146:912-8.
8. Perera FP, Poirier MC, Yuspa SH, Nakayama J, Jaretzki A, Curnen MM, et al. A pilot project in molecular cancer epidemiology: determination of benzo[a]pyrene-DNA adducts in animal and human tissues by immunoassays. Carcinogenesis 1982;3:1405-10.
9. Herron DC, Shank RC. Methylated purines in human liver DNA after probable dimethylnitrosamine poisoning. Cancer Res 1980;40:3116-7.
10. Shields PG, Harris CC. Molecular epidemiology and the genetics of environmental cancer. JAMA 1991;266:681-7.
11. McMichael AJ. Invited commentary - "molecular epidemiology": new pathway or new travelling companion? Am J Epidemiol 1994;140:1-11.
12. American Cancer Society. Cancer facts & figures, 1999. Atlanta (GA): American Cancer Society; 1999.
13. Hiatt H, Watson JD, Winsten JA, editors. Origins of human cancer. Cold Spring Harbor (NY): Cold Spring Harbor Laboratories; 1977.
14. Weinstein IB, Santella RM, Perera FP. The molecular biology and molecular epidemiology of cancer. In: Greenwald P, Kramer BS, Weed DL, editors. The science and practice of cancer prevention and control. New York (NY): Marcel-Dekker; 1993.
15. Tomatis L, Aitio A, Wilbourn J, Shukar L. Human carcinogens so far identified. Jpn J Cancer Res 1989;80:795-807.
16. US Public Health Service (PHS). Smoking and health. Report of the Advisory Committee to the Surgeon General of the Public Health Service. Washington (DC): PHS; 1964.
17. National Research Council, National Academy of Sciences. Environmental tobacco smoke: measuring exposures and assessing health effects. Washington (DC): National Academy Press; 1986.
18. Hecht SS. Tobacco smoke carcinogens and lung cancer. J Natl Cancer Inst 1999;91:1194-210.
19. International Agency for Research on Cancer. Polynuclear aromatic compounds, part 1: chemical, environmental and experimental data. IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans. Lyon (France): International Agency for Research on Cancer; 1983.
20. Environmental Protection Agency. Aerometric Information Retrieval System (AIRS), data for 1985-1990. Research Triangle Park (NC): Environmental Protection Agency; 1990.
21. Miller EC, Miller JA. Mechanisms of chemical carcinogenesis. Cancer 1981;47(5 Suppl):1055-64.
22. Perera FP. Environment and cancer: who are susceptible? Science 1997; 278:1068-73.
23. Perera FP, Santella RM, Brenner D, Poirier MC, Munshi AA, Fischman HK, et al. DNA adducts, protein adducts, and sister chromatid exchange in cigarette smokers, and nonsmokers. J Natl Cancer Inst 1987;79:449-56.
24. Mumford JL, Lee X, Lewtas J, Young TL, Santella RM. DNA adducts as biomarkers for assessing exposure to polycyclic aromatic hydrocarbons in tissues from Xuan Wei women with high exposure to coal combustion emissions and high lung cancer mortality. Environ Health Perspect 1993; 99:83-7.
25. Binkova B, Lewtas J, Miskova I, Rossner P, Cerna M, Mrackove G, et al. Biomarker studies in northern Bohemia. Environ Health Perspect 1996;104 Suppl 3:591-7.
26. Perera FP, Hemminki K, Grzybowska E, Motykiewicx G, Michalska J, Santella RM, et al. Molecular and genetic damage in humans from environmental pollution in Poland. Nature 1992;360:256-8.
27. Dickey C, Santella RM, Hattis D, Tang D, Hsu Y, Cooper T, et al. Variability in PAH-DNA adduct measurements in peripheral mononuclear cells: implications for quantitative cancer risk assessment. Risk Anal 1997;17:649-56.
28. Kriek E, van Schooten FJ, Hillebrand MJ, Van Leeuwen FE, Den Engelse L, De Looff AJ, et al. DNA adducts as a measure of lung cancer risk in humans exposed to polycyclic aromatic hydrocarbons. Environ Health Perspect 1993;99:71-5.
29. Tang D, Santella RM, Blackwood AM, Young TL, Mayer J, Jaretzki A, et al. A molecular epidemiological case-control study of lung cancer. Cancer Epidemiol Biomarkers Prev 1995;4:341-6.
30. Bartsch H, Rojas M, Alexandrov K, Risch A. Impact of adduct determination on the assessment of cancer susceptibility. Recent Results Cancer Res 1998;154:86-96.
31. Kellermann G, Shaw CR, Luyten-Kellermann M. Aryl hydrocarbon hydroxylase inducibility and bronchogenic carcinoma. N Engl J Med 1973; 289:934-7.
32. Khoury MJ. From genes to public health: the applications of genetic technology in disease prevention. Genetics Working Group. Am J Public Health 1996;86:1717-22.
33. Vineis P, Malats N, Porta M, Real FX. Human cancer, carcinogenic exposures and mutation spectra. Mutat Res 1999;436:185-94.
34. Greenblatt MS, Bennett WP, Hollstein M, Harris CC. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 1994;55:4855-78.
35. Denissenko MF, Pao A, Tang M, Pfeifer GP. Preferential formation of benzo|a|pyrene adducts at lung cancer mutational hotspots in P53. Science 1996;274:430-2.
36. Stowers SJ, Anderson MW. Ubiquitous binding of benzo[a]pyrene metabolites to DNA and protein in tissues of the mouse and rabbit. Chem Biol Interact 1984;51:151-66.
37. Wiencke JK, Thurston SW, Kelsey KT, Varkonyi A, Wain JC, Mark EJ, et al. Early age at smoking initiation and tobacco carcinogen DNA damage in the lung. J Natl Cancer Inst 1999;91:614-9.
38. Palmer JR, Rosenberg L. Cigarette smoking and the risk of breast cancer. Epidemiol Rev 1993;15:145-56.
39. Morabia A, Bernstein M, Heritier S, Khatchatrian N. Relation of breast cancer with passive and active exposure to tobacco smoke. Am J Epidemiol 1996;143:918-28.
40. Ambrosone CB, Freudenheim JL, Graham S, Marshal JR, Vena JE, Brasure JR. et al. Cigarette smoking, N-acetyltransferase 2 genetic polymorphisms, and breast cancer risk. JAMA 1996;276:1494-501.
41. Moore CJ, Tricomi WA, Gould MN. Interspecies comparison of polycyclic aromatic hydrocarbon metabolism in human and rat mammary epithelial cells. Cancer Res 1986;46:4946-52.
42. el-Bayoumy K. Environmental carcinogens that may be involved in human breast cancer etiology. Chem Res Toxicol 1992;5:585-90.
43. Perera FP, Estabrook A, Hewer A, Channing K, Rundle A, Mooney LA, et al. Carcinogen-DNA adducts in human breast tissue. Cancer Epidemiol Biomarkers Prev 1995;4:233-8.
44. Phillips DH, Castegnaro M. Standardization and validation of DNA adduct postlabelling methods: report of interlaboratory trials and production of recommended protocols. Mutagenesis 1999;14:301-15.
45. Li D, Wang M, Dhingra K, Hittelman WN. Aromatic DNA adducts in adjacent tissues of breast cancer patients: clues to breast cancer etiology. Cancer Res 1996;56:287-93.
46. Zhang YJ, Hsu TM, Santella RM. Immunoperoxidase detection of polycyclic aromatic hydrocarbon-DNA adducts in oral mucosa cells of smokers and nonsmokers. Cancer Epidemiol Biomarkers Prev 1995;4:133-8.
47. Romano G, Sgambato A, Boninsegna A, Flamini G, Curigliano G, Yang Q, et al. Evaluation of polycyclic aromatic hydrocarbon-DNA adducts in exfoliated oral cells by an immunohistochemical assay. Cancer Epidemiol Biomarkers Prev 1999;8:91-6.
48. Guinee DG Jr, Travis WD, Trivers GE, De Benedetti VM, Cawley H, Welsh JA, et al. Gender comparisons in human lung cancer: analysis of p53 mutations, anti-p53 serum antibodies and C-erbB-2 expression. Carcinogenesis 1995;16:993-1002.
49. Hennekens CH, Buring JE, Manson JE, Stampfer M, Rosner B, Cook NR, et al. Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. N Engl J Med 1996;334:1145-9.
50. Gammon, M. The Long Island Breast Cancer Project. October 29, 1999 (available from URL: http://www.dccps.ims.nic.nih.gov/LIBCSP/ index.html).
51. Wild C, Hasegawa R, Barraud L, Chutimataewin S, Chapot B, Ito N, et al. Aflatoxin-albumin adducts: a basis for comparative carcinogenesis between animals and humans. Cancer Epidemiol Biomarkers Prev 1996;5: 179-89.
52. Ross RK, Yuan JM, Yu MC, Wogan GN, Qian GS, Tu JT, et al. Urinary aflatoxin biomarkers and risk of hepatocellular carcinoma. Lancet 1992; 339:943-6.
53. Qian GS, Ross RK, Yu MC, Yuan JM, Gao YT, Henderson BE, et al. A follow-up study of urinary markers of aflatoxin exposure and liver cancer risk in Shanghai, People's Republic of China. Cancer Epidemiol Biomarkers Prev 1994;3:3-10.
54. Wang LY, Hatch M, Chen CJ, Levin B, You SL, Lu SN, et al. Aflatoxin exposure and risk of hepatocellular carcinoma in Taiwan. Int J Cancer 1996;67:620-5.
55. Yu MW, Lien JP, Chiu YH, Santella RM, Liaw YF, Chen CJ. Effect of aflatoxin metabolism and DNA adduct formation on hepatocellular carcinoma among chronic hepatitis B carriers in Taiwan. J Hepatol 1997;27: 320-30.
56. Hussain SP, Harris CC. Molecular epidemiology of human cancer. Toxicol Lett 1998;102-103:219-25.
57. Hagmar L, Bonassi S, Stromberg U, Brogger A, Knudsen LE, Norppa H, et al. Chromosomal aberrations in lymphocytes predict human cancer: a report from the European Study Group on Cytogenetic Biomarkers and Health (ESCH). Cancer Res 1998;58:4117-21.
58. Bonassi S, Abbondandolo A, Camurri L, Dal Pra L, De Ferrari M, Degrassi F, et al. Are chromosome aberrations in circulating lymphocytes predictive of future cancer onset in humans? Preliminary results of an Italian cohort study. Cancer Genet Cytogenet 1995;79:133-5.
59. Smith MT, Zhang L. Biomarkers of leukemia risk: benzene as a model. Environ Health Perspect 1998;106 Suppl 4:937-46.
60. Zahm SH, Devesa SS. Childhood cancer: overview of incidence trends and environmental carcinogens. Environ Health Perspect 1995;103 Suppl 6:177-84.
61. Hilden JM, Frestedt JL, Kersey JH. Molecular analysis of infant acute leukemia. Leuk Lymphoma 1997;25:191-9.
62. Taki T, Kano H, Taniwaki M, Sako M, Yanagisawa M, Hayashi Y. AF5q31, a newly identified AF-4 related gene, is fused to MLL in infant acute lymphoblastic leukemia with ins(5;11)(q31;q13q23). Proc Natl Acad Sci USA 1999;96:14535-40.
63. Gale KB, Ford AM, Repp R, Borkhardt A, Keller C, Eden OB, et al. Backtracing leukemia to birth: identification of clonotypic gene fusion sequences in neonatal blood spots. Proc Natl Acad Sci USA 1997;94: 13950-4.
64. Smith MT. The mechanism of benzene-induced leukemia: a hypothesis and speculations on the causes of leukemia. Environ Health Perspect 1996;104 Suppl 6:1219-25.
65. Garte S, Zocchetti C, Taioli E. Gene-environment interactions in the application of biomarkers of cancer susceptibility in epidemiology. In: Toniolo P, Boffetta P, Shuker DE, Rothman N, Hulka B, Pearce N, editors. Application of biomarkers in cancer epidemiology. Lyon (France): IARC Sci Publ; 1997.
66. Caporaso N, Goldstein A. Issues involving biomarkers in the study of the genetics of human cancer. IARC Sci Publ 1997;142:237-50.
67. Schulte PA, Hunter D, Rothman N. Ethical and social issues in the use of biomarkers in epidemiological studies. In: Toniolo P, Boffetta P, Shuker DE, Rothman N, Hulka B, Pearce N, editors. Application of biomarkers in cancer epidemiology. Lyon (France): IARC Sci Publ; 1997.
68. Kawajiri K, Fujii-Kuriyama Y. P450 and human cancer. Jpn J Cancer Res 1991;82:1325-35.
69. Xu X, Kelsey KT, Wiencke JK, Wain JC, Christiani DC. Cytochrome P450 CYP1A1 Msp1 polymorphism and lung cancer susceptibility. Cancer Epidemiol Biomarkers Prev 1996;5:687-92.
70. Mooney LA, Bell DA, Santella RM, Van Bennekum AM, Ottman R, Paik M, et al. Contribution of genetic and nutritional factors to DNA damage in heavy smokers. Carcinogenesis 1997;18:503-9.
71. Whyatt RM, Santella RM, Bell DA, Garte SJ, Jedrychowski W, Yarborough A, et al. Biomarkers of exposures and susceptibility in newborns [abstract]. Proc Am Assoc Cancer Res 1996;37:250.
72. Bartsch H, Hietanen E. The role of individual susceptibility in cancer burden related to environmental exposure. Environ Health Perspect 1996;104 Suppl 3:569-77.
73. Kawajiri K, Eguchi H, Nakachi K, Sekiya T, Yamamoto M. Association of CYP1A1 germ line polymorphisms with mutations of the p53 gene in lung cancer. Cancer Res 1996;56:72-6.
74. Spivack SD, Fasco MJ, Walker VE, Kaminsky LS. The molecular epidemiology of lung cancer. Crit Rev Toxicol 1997;27:319-65.
75. McWilliams JE, Sanderson BJ, Harris EL, Richert-Boe KE, Henner WD. Glutathione S-transferase M1 (GSTM1) deficiency and lung cancer risk. Cancer Epidemiol Biomarkers Prev 1995;4:589-94.
76. Ryberg D, Hewer A, Phillips DH, Haugen A. Different susceptibility to smoking-induced DNA damage among male and female lung cancer patients. Cancer Res 1994;54:5801-3.
77. Kato S, Bowman ED, Harrington AM, Blomeke B, Shields PG. Human lung carcinogen-DNA adduct levels mediated by genetic polymorphisms in vivo. J Natl Cancer Inst 1995;87:902-7.
78. Hayashi S, Watanabe J, Kawajiri K. High susceptibility to lung cancer analyzed in terms of combined genotype of P4501A1 and Mu-class glutathione S-transferase genes. Jpn J Cancer Res 1992;83:866-70.
79. Garcia-Closas M, Kelsey KT, Wiencke JK, Xu X, Wain JC, Christiani DC. A case-control study of cytochrome P450 1A1, glutathione S-transferase M1, cigarette smoking and lung cancer susceptibility. Cancer Causes Control 1997;8:544-53.
80. Ishibe N, Wiencke JK, Zuo ZF, McMillan A, Spitz M, Kelsey KT. Susceptibility to lung cancer in light smokers associated with CYP1A1 polymorphisms in Mexican- and African-Americans. Cancer Epidemiol Biomarkers Prev 1997;6:1075-80.
81. Mohrenweiser HW, Jones IM. Variation in DNA repair is a factor in cancer susceptibility: a paradigm for the promises and perils of individual and population risk estimation? Mutat Res 1998;400:15-24.
82. Dybdahl M, Vogel U, Frentz G, Wallin H, Nexo B. Polymorphisms in the DNA repair gene XPD: correlations with risk and age at onset of basal cell carcinoma. Cancer Epidemiol Biomarkers Prev 1999;8:77-81.
83. 1-DNA adducts and glycophorin A variant frequency. Cancer Res 1999;59:2557-61.
84. Wei Q, Cheng L, Hong WK, Spitz MR. Reduced DNA repair capacity in lung cancer patients. Cancer Res 1996;56:4103-7.
85. Vahakangas K, Pelkonen O. Host variations in carcinogen metabolism and DNA repair. In: Lynch HT, Hirayama T, editors. Genetic epidemiology of cancer. Boca Raton (FL): CRC Press; 1989. p. 35-54.
86. Wei Q, Gu J, Cheng L, Bondy ML, Jiang H, Hong WK, et al. Benzo(a) pyrene diol epoxide-induced chromosomal aberrations and risk of lung cancer. Cancer Res 1996;56:3975-9.
87. Hecht SS, Carmella SG, Akerkar S, Richie JP. 4-(Methylnitrosamino)-1-(3,pyridyl)-1-butanol (NNAL) and its glucuronide, metabolites of a tobacco-specific lung carcinogen, in the urine of black and white smokers [abstract]. Proc Am Assoc Cancer Res 1994;35:286.
88. Zang EA, Wynder EL. Differences in lung cancer risk between men and women: examination of the evidence. J Natl Cancer Inst 1996;88:183-92.
89. Kure EH, Ryherg D, Hewer A, Phillips DH, Skaug V, Baera R, et al. p53 mutations in lung tumours: relationship to gender and lung DNA adduct levels. Carcinogenesis 1996;17:2201-5.
90. Mollerup S, Ryberg D, Hewer A, Phillips D, Haugen A. Sex differences in lung CYP1A1 expression and DNA adduct levels among lung cancer patients. Cancer Res 1999;59:3317-20.
91. Tang DL, Rundle A, Warburton D, Santella RM, Tsai WY, Chiamprasert S, et al. Associations between both genetic and environmental biomarkers and lung cancer: evidence of a greater risk of lung cancer in women smokers. Carcinogenesis 1998;19:1949-53.
92. Block G. Micronutrients and cancer: time for action [editorial]. J Natl Cancer Inst 1993;85:846-8.
93. Mooney LA, Perera FP. Application of molecular epidemiology to lung cancer prevention. J Cell Biochem Suppl 1996;25:63-8.
94. Grinberg-Funes R, Singh VN, Perera FP, Bell DA, Young TL, Dickey C, et al. Polycyclic aromatic hydrocarbon-DNA adducts in smokers and their relationship to micronutrient levels and the glutathione-S-transferase M1 genotype. Carcinogenesis 1994;15:2449-54.
95. Kucuk O, Pung A, Franke AA, Custer LJ, Wilkens LR, Le Marchand L, et al. Correlations between mutagen sensitivity and plasma nutrient levels of healthy individuals. Cancer Epidemiol Biomarkers Prev 1995;4: 217-21.
96. Taioli E, Trachman J, Chen X, Toniolo P, Garte SJ. A CYP1A1 restriction fragment length polymorphism is associated with breast cancer in African-American women. Cancer Res 1995;55:3757-8.
97. Ishibe N, Hankinson SE, Colditz GA, Spiegelman D, Willett WC, Speizer FE, et al. Cigarette smoking, cytochrome P450 1A1 polymorphisms, and breast cancer risk in the Nurses' Health Study. Cancer Res 1998;58: 667-71.
98. Ambrosone CB, Freudenheim JL, Graham S, Marshall JR, Vena JE, Brasure JR, et al. Cytochrome P4501A1 and glutathione S-transferase (M1) genetic polymorphisms and postmenopausal breast cancer risk. Cancer Res 1995;55:3483-5.
99. Helzlsouer KJ, Selmin O, Huang HY, Strickland PT, Hoffman S, Alberg AJ, et al. Association between glutathione S-transferase M1, P1 and T1 genetic polymorphisms and development of breast cancer. J Natl Cancer Inst 1998;90:512-8.
100. Yu MC, Skipper PL, Taghizadeh K, Tannenbaum SR, Chan KK, Henderson BE, et al. Acetylator phenotype, aminobiphenyl-hemoglobin adduct levels, and bladder cancer risk in white, black, and Asian men in Los Angeles, California. J Natl Cancer Inst 1994;86:712-6.
101. Nebert DW, Puga A, Vasiliou V. Role of the Ah receptor and the dioxin-inducible [Ah] gene battery in toxicity, cancer, and signal transduction. Ann NY Acad Sci 1993;685:624-40.
102. Taioli E, Bradlow HL, Garbers SV, Sepkovic DW, Osborne MP, Trachman J, et al. Role of estradiol metabolism and CYP1A1 polymorphisms in breast cancer risk. Cancer Detect Prev 1999;23:232-7.
103. Blaszyk H, Vaughn CB, Hartmann A, McGovern RM, Schroeder JJ, Cunningham J, et al. Novel pattern of p53 gene mutations in an American black cohort with high mortality from breast cancer. Lancet 1994;343: 1195-7.
104. Ambrosone CB, Shields PG. Molecular epidemiology of breast cancer. Prog Clinic Biol Res 1997;396:83-99.
105. Wolff MS, Weston A. Breast cancer risk and environmental exposures. Environ Health Perspect 1997;105:891-6.
106. Welp EA, Weiderpass E, Boffetta P, Vainio H, Vasama-Neuvonen K. Petralia S, et al. Environmental risk factors of breast cancer. Scand J Work Environ Health 1998;24:3-7.
107. Laden F, Hunter DJ. Environmental risk factors and female breast cancer. Annu Rev Public Health 1998;19:101-23.
108. Yu MN, Chiu YH, Chiang YC, Chen CH, Lee TH, Santella RM, et al. Plasma carotenoids, glutathione S-transferase M1 and T1 genetic polymorphisms, and risk of hepatocellular carcinoma: independent and interactive effects. Am J Epidemiol 1999;149:621-9.
109. 1. Proc Natl Acad Sci U S A 1995;92:2384-7.
110. Yu MW, Gladek-Yarborough A, Chiamprasert S, Santella RM, Liaw YF, Chen CJ. Cytochrome P450 2E1 and glutathione S-transferase M1 polymorphisms and susceptibility to hepatocellular carcinoma. Gastroenterology 1995;109:1266-73.
111. Ross D. Metabolic basis of benzene toxicity. Eur J Haematol Suppl 1996; 60:111-8.
112. 609 C→T mutation and rapid fractional excretion of chlorzoxazone. Cancer Res 1997;57:2839-42.
113. National Research Council. Science and judgement in risk assessment. Washington (DC): National Academy Press; 1994.
114. Goldman LR. Children - unique and vulnerable. Environmental risks facing children and recommendations for response. Environ Health Perspect 1995;103(S6):13-8.
115. Perera FP. Molecular epidemiology: insights into cancer susceptibility, risk assessment, and prevention. J Natl Cancer Inst 1996;88:496-509.
116. Perera FP, Jedrychowski W, Rauh V, Whyatt RM. Molecular epidemiologic research on the effects of environmental pollutants on the fetus. Environ Health Perspect 1999;107(S3):451-60.
117. Shimizu Y, Kato H, Schull WJ. Risk of cancer among atomic bomb survivors. J Radiat Res (Tokyo) 1991;32(S2):54-63.
118. Hegmann KT, Fraser AM, Keaney RP, Moser SE, Nilasena DS, Sedlars M, et al. The effect of age at smoking initiation on lung cancer risk. Epidemiology 1993;4:444-8.
119. Mooney LA, Santella RM, Covey L, Jeffrey AM, Bigbee W, Randall MC, et al. Decline of DNA damage and other biomarkers in peripheral blood following smoking cessation. Cancer Epidemiol Biomarkers Prev 1995; 4:627-34.
120. Perera FP, Dickey C, Santella R, O'Neill JP, Albertini RJ, Ottman R, et al. Carcinogen-DNA adducts and gene mutation in foundry workers with low-level exposure to polycyclic aromatic hydrocarbons. Carcinogenesis 1994;15:2905-10.
121. Groopman JD, Kensler TW. The light at the end of the tunnel for chemical-specific biomarkers: daylight or headlight? Carcinogenesis 1999;20: 1-11.
122. Kensler TW, Gange SJ, Egner PA, Dolan PM, Munoz A, Groopman JD, et al. Predictive value of molecular dosimetry: individual versus group effects of oltipraz on aflatoxin-albumin adducts and risk of liver cancer. Cancer Epidemiol Biomarkers Prev 1997;6:603-10.
123. Zhang BC, Zhu YR, Wang JB, Wu Y, Zhang QN, Qian GS, et al. Oltipraz chemoprevention trial in Qidong, Jiangsu Province, People's Republic of China. J Cell Biochem Suppl 1997;28-29:166-73.
124. Wang JS, Shen X, He X, Zhu YR, Zhang BC, Wang JB, et al. Protective alterations in phase 1 and 2 metabolism of aflatoxin B1 by oltipraz in residents of Qidong, People's Republic of China. J Natl Cancer Inst 1999; 91:347-54.
125. Khuri FR, Kurie JM, Hong WK. Chemoprevention of respiratory tract cancer. Hematol Oncol Clin North Am 1997;11:387-408.
126. Boone CW, Kelloff GJ. Biomarker end-points in cancer chemoprevention trials. IARC Sci Publ 1997;142:273-80.
127. Gritz ER, Joseph W. Cullen Memorial Award Lecture. Paving the road from basic research to policy: cigarette smoking as a prototype issue for cancer control science. Cancer Epidemiol Biomarkers Prev 1992;1: 427-34.
128. Perera FP, Mooney LA. The role of molecular epidemiology in cancer prevention. In: DeVita VT Jr, Hellman S, Rosenberg SA, editors. Cancer prevention. Philadelphia (PA): Lippincott; 1993. p. 1-15.
129. Pirkle JL, Kaufmann RB, Brody DJ, Hickman T, Gunter EW, Paschal DC. Exposure of the U.S. population to lead, 1991-1994. Environ Health Perspect 1998;106:745-50.
130. Perera FP, Whyatt RM, Jedrychowski W, Rauh V, Manchester D, Santella RM, et al. Recent developments in molecular epidemiology: a study of the effects of environmental polycyclic aromatic hydrocarbons on birth outcomes in Poland. Am J Epidemiol 1998;147:309-14.
131. Weinstein IB, Zhou P. Cell cycle control gene defects and human cancer. Encyclopedia of cancer. New York (NY): Academic Press; 1997.
132. National Research Council, National Academy of Sciences. Pesticides in the diets of infants and children. Washington (DC): National Academy Press; 1993.
133. Olden K, Poje J. Environmental justice and environmental health. Bull Soc Occup Environ Health 1995;4:3-4.
134. Hattis D. Human interindividual variability in susceptibility to toxic effects: from annoying detail to a central determinant of risk. Toxicology 1996;111:5-14.
135. Portier CJ, Bell DA. Genetic susceptibility: significance in risk assessment. Toxicol Lett 1998;102-103:185-9.
136. Hattis D, Barlow K. Human interindividual variability in cancer risks. Technical and management challenges. Health Ecologic Risk Assess 1996;2:194-220.
137. Hattis D. Use of biological markers and pharmacokinetics in human health risk assessment. Environ Health Perspect 1991;90:229-38.
138. Goldman LR. Chemicals and children's environment: what we don't know about risks. Environ Health Perspect 1998;106 Suppl 3:875-80.
139. Garcia-Closas M, Lubin JH. Power and sample size calculations in case-control studies of gene-environment interactions: comments on different approaches. Am J Epidemiol 1999;149:689-92.
140. Environmental Genome Project advances. Environ Health Perspect 1997; 105:1298.
141. Carroquino MJ, Galson SK, Licht J, Amler RW, Perera FP, Claxton LD, et al. The U.S. EPA Conference on Preventable Causes of Cancer in Children: a research agenda. Environ Health Perspect 1998;106 Suppl 3:867-73.